**: Pharmaceutical Intelligence Industry Observation***
Photo.com.
Industry indicators
From the perspective of regional industrial distribution, as of the end of November 2023, Zhongshan has 385 enterprises related to the biomedical industry (the scope of enterprise statistical indicators is mainly production and R&D enterprises, the same below).
From the perspective of enterprise qualification distribution, as of the end of November 2023, in the field of biomedical industry, there are 73 high-tech enterprises in Zhongshan, 25 specialized and special new enterprises, and 3 gazelle enterprises.
Fig.1 Distribution of biomedical industry qualifications in Zhongshan.
Pharmaceutical Intelligence Data - Regional Industry Analysis System.
From the perspective of product type distribution, as of the end of November 2023, there are 38 enterprises producing chemical drugs, 24 traditional Chinese medicine enterprises, 9 biological product enterprises, 15 API enterprises, 298 medical device enterprises, 15 pharmaceutical packaging material enterprises, 6 pharmaceutical excipient enterprises, and 27 health care product enterprises.
Fig.2 Distribution of biomedical industry enterprises in Zhongshan City.
Pharmaceutical Intelligence Data - Regional Industry Analysis System.
From the perspective of R&D capabilities, as of the end of November 2023, Zhongshan has 892 patents in the field of biomedical industry, 4 new drugs on the market, 695 domestic medical devices on the market (based on registration certificates), and 74 generic drugs that have passed the consistency evaluation (based on acceptance numbers).
Fig.3 R&D of biomedical industry in Zhongshan.
Pharmaceutical Intelligence Data - Regional Industry Analysis System.
From the perspective of clinical drug applications, from 2016 to 2023, the total number of clinical drug applications in Zhongshan is 50 (in terms of varieties). Among all cities in the country, Zhongshan ranks 23rd.
Fig.4 Clinical quantity of drug applications in Zhongshan City.
Pharmaceutical Intelligence Data - Regional Industry Analysis System.
From the perspective of drug approval clinics, from 2016 to 2023, the total number of drug approved clinics in Zhongshan City is 55 (in terms of varieties). Among all cities in the country, Zhongshan ranks 34th.
Fig.5 Clinical quantity of drugs approved in Zhongshan City.
Pharmaceutical Intelligence Data - Regional Industry Analysis System.
From the perspective of drug clinical trials, from 2016 to 2023, the total number of drug clinical trials in Zhongshan is 119 (in terms of varieties). Among all cities in the country, Zhongshan ranks 35th.
Fig.6 Number of drug clinical trials in Zhongshan.
Pharmaceutical Intelligence Data - Regional Industry Analysis System.
From the perspective of drug application and marketing, from 2016 to 2023, the total number of drug application applications in Zhongshan City is 105 (in terms of variety). Among all cities in the country, Zhongshan ranks 23rd.
Fig.7 The number of drug applications in Zhongshan City.
Pharmaceutical Intelligence Data - Regional Industry Analysis System.
From the perspective of drug approval, from 2018 to 2023, the total number of drugs approved for marketing in Zhongshan City is 49 (in terms of varieties). Among all cities in the country, Zhongshan ranks 31st.
Fig.8 The number of drugs approved for marketing in Zhongshan City.
Pharmaceutical Intelligence Data - Regional Industry Analysis System.
From the perspective of the consistency evaluation of generic drugs, the total number of generic drugs in Zhongshan City that have passed the consistency evaluation is 74 (based on the acceptance number). Among all cities in the country, Zhongshan ranks 26th.
Fig.9 The number of generic drugs in Zhongshan City that passed the consistency evaluation.
Pharmaceutical Intelligence Data - Regional Industry Analysis System.
From the perspective of medical device listings, the total number of medical devices listed in Zhongshan City is 695. Among all cities in the country, Zhongshan ranks 36th.
Figure 10 The number of medical devices listed in Zhongshan.
Pharmaceutical Intelligence Data - Regional Industry Analysis System.
From the perspective of investment and financing, the cumulative investment and financing amount of Zhongshan is 394.4 billion. Among all cities in the country, Zhongshan ranks 34th.
Figure 11 Investment and financing in Zhongshan.
Pharmaceutical Intelligence Data - Regional Industry Analysis System.
From the perspective of hospital sales market value, the hospital sales market amount in Zhongshan City is 303800 million, among all cities in the country, Zhongshan ranks 43rd;From the perspective of centralized procurement amount, the centralized procurement amount in Zhongshan City is 76.9 billion, among all cities in the country, Zhongshan ranks 18th.
Fig.12 Zhongshan Hospital Sales Market Centralized Bid Winning Amount.
Pharmaceutical Intelligence Data - Regional Industry Analysis System.
Industrial layout
After years of development, Zhongshan has formed an industrial pattern dominated by pharmaceuticals, medical devices, and medical information, with coordinated development of health food and cosmetics, pharmaceutical circulation, and health service industries, and has introduced and cultivated a number of leading and unique enterprises.
In the field of pharmaceuticals, it has gathered many well-known enterprises at home and abroad, such as Novartis Sandoz, Swiss Ferring, Akeso, Zhongzhi Pharmaceutical, etcIn the field of medical devices, it has gathered the first domestic three-dimensional digital breast machine with independent intellectual property rights, such as Daying Medical, the gene sequencer technology, and the leading domestic Tengfei Gene.
In terms of the construction of industrial parks, it has the carriers of biomedical industrial parks such as the National Health Science and Technology Industrial Base, Zhongshan Life Science Park, and South China Modern Chinese Medicine City.
1. High-tech Zone
The total planning area of the national health science and technology industrial base is 135 square kilometers. After more than 20 years of construction, the base has become a comprehensive health industry park with international influence and a leading domestic health industry, forming an industrial cluster pattern dominated by biomedicine, medical equipment, special food, cosmetics and health service industry.
It has gathered a large number of industry leaders, including Novartis Sandoz Pharmaceutical, Ferring Pharmaceutical, Akeso, Zhonghao Pharmaceutical, Anshi Pharmaceutical, Xinghao Pharmaceutical, Jincheng Pharmaceutical, Mingfeng Medical, Lexin Medical, Bailing Biotechnology, etc.
Fig.13 Zhongshan National Health Science and Technology Industrial Base.
The official website of Zhongshan Municipal Bureau of Industry and Information Technology.
2. Cuiheng New District
Cuiheng New Area cultivates the health and pharmaceutical industry as a leading industry, forms a development environment characterized by special policies and first-class clusters, creates agglomeration platforms such as Zhongshan Life Science Park and Xiwan Pharmaceutical and Health Theme Industrial Park, and introduces and cultivates leading enterprises in the pharmaceutical field such as Akeso, Wanhan Pharmaceutical, and CrownBio.
Zhongshan Life Science Park is positioned to build a benchmark pharmaceutical professional park in the Greater Bay Area, aiming at the frontier of biomedical technology, focusing on attracting innovative drug projects represented by small molecules, macromolecules and cell genes, etc., and medical device projects represented by high-end medical equipment, high-value consumables, innovative D, etc. The innovation achievements of Wanhan Pharmaceutical and other pharmaceutical companies are in the leading position in the industry in the country and even the world.
Fig.14 Zhongshan Life Science Park.
The official website of Tsui Heng Group.
Akeso Bay Area Science and Technology Park is invested by Akeso Biopharma to build a digital intelligent production base with a total planned production capacity of more than 100,000 liters, integrating the research and development of innovative antibody drugs, the production and sales of drug substance and preparations, and plans to build a biomedical innovation, R&D and industrialization base with a leading global technology level.
Author |Sun Yang.
Edit |Aster.
Cooperative Consulting:Disclaimer: This article is the content of Yaozhi.com**, and the copyright of the text belongs to the original author, and the purpose is to convey more information, and it does not represent the position of Yaozhi.com. If it involves the content of the work, copyright and other issues, please leave a message on this platform, and we will delete it as soon as possible.